| [1] |
Ng JH, Iyer NG, Tan MH, et al. Changing epidemiology of oral squamous cell carcinoma of the tongue: A global study[J]. Head Neck, 2017, 39(2): 297-304.
|
| [2] |
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA A Cancer J Clin, 2024, 74(1): 12-49.
|
| [3] |
da Silva Souto AC, Vieira Heimlich F, Lima de Oliveira L, et al. Epidemiology of tongue squamous cell carcinoma: A retrospective cohort study[J]. Oral Dis, 2023, 29(2): 402-410.
|
| [4] |
Huang ZS, Chen WL, Huang ZQ, et al. Dysphagia in tongue cancer patients before and after surgery[J]. J Oral Maxillofac Surg, 2016, 74(10): 2067-2072.
|
| [5] |
Wang J, Luo H, Liu F, et al. Quality of life in oral cancer patients-effects of tongue resection and sociocultural aspects[J]. J Craniofac Surg, 2013, 24(5): e493-e496.
|
| [6] |
Hartner L. Chemotherapy for oral cancer[J]. Dent Clin North Am, 2018, 62(1): 87-97.
|
| [7] |
Aminuddin A, Ng PY, Leong CO, et al. Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma[J]. Sci Rep, 2020, 10(1): 7885.
|
| [8] |
Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557-4566.
|
| [9] |
Flem-Karlsen K, Fodstad Ø, Tan M, et al. B7-H3 in cancer–beyond immune regulation[J]. Trends Cancer, 2018, 4(6): 401-404.
|
| [10] |
Koumprentziotis IA, Theocharopoulos C, Foteinou D, et al. New emerging targets in cancer immunotherapy: The role of B7-H3[J]. Vaccines, 2024, 12(1): 54.
|
| [11] |
Jiang Y, Liu JY, Chen LY, et al. A promising target for breast cancer: B7-H3[J]. BMC Cancer, 2024, 24(1): 182.
|
| [12] |
Huang MY, Luo JH, Ji XP, et al. Deficiency of tumor-expressed B7-H3 augments anti-tumor efficacy of anti-PD-L1 monotherapy rather than the combined chemoimmunotherapy in ovarian cancer[J]. Pharmacol Res, 2022, 186: 106512.
|
| [13] |
Wang RQ, Ma YC, Zhan SH, et al. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression[J]. Cell Death Dis, 2020, 11(1): 55.
|
| [14] |
Chen JT, Chen CH, Ku KL, et al. Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response[J]. Proc Natl Acad Sci USA, 2015, 112(42): 13057-13062.
|
| [15] |
Huang SH, O'Sullivan B. Overview of the 8th edition TNM classification for head and neck cancer[J]. Curr Treat Options Oncol, 2017, 18(7): 40.
|
| [16] |
Paderno A, Morello R, Piazza C. Tongue carcinoma in young adults: A review of the literature[J]. Acta Otorhinolaryngol Ital, 2018, 38(3): 175-180.
|
| [17] |
Zhou WT, Jin WL. B7-H3/CD276: An emerging cancer immunotherapy[J]. Front Immunol, 2021, 12: 701006.
|
| [18] |
Liu C, Zhang GW, Xiang KH, et al. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy[J]. Cancer Immunol Immunother, 2022, 71(7): 1549-1567.
|
| [19] |
Castellanos JR, Purvis IJ, Labak CM, et al. B7-H3 role in the immune landscape of cancer[J]. Am J Clin Exp Immunol, 2017, 6(4): 66-75.
|
| [20] |
Getu AA, Tigabu A, Zhou M, et al. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development[J]. Mol Cancer, 2023, 22(1): 43.
|
| [21] |
Liu H, Tekle C, Chen YW, et al. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation[J]. Mol Cancer Ther, 2011, 10(6): 960-971.
|
| [22] |
Zhang PF, Chen Z, Ning K, et al. Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells[J]. Biochem Biophys Res Commun, 2017, 490(3): 1132-1138.
|
| [23] |
Sun ZZ, Zhang T, Ning K, et al. B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu[J]. Oncol Rep, 2016, 36(1): 231-238.
|